Silverarc Capital Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 13, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Silverarc Capital Management reported a $899M portfolio of 65 positions to the SEC as of the end of Q2 2026. Its largest positions are ASND, CELC, COGT. During the quarter it opened Enliven Therapeutics and Sagimet Biosciences and exited Nuvalent and Scholar Rock Holding.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Silverarc Capital Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
- 13G/AKalVista PharmaceuticalsKALV0 %
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
Stake reported in the company · event of Jun 30, 2026 · filed Aug 14, 2026 · filing ↗
What changed this quarter
79 positions with a change (17 new, 16 added to, 27 trimmed, 19 sold); also, 2 entered through an IPO, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAvalyn PharmaAVLN1.2% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Nuvalent−4.0 ppof portfolioSold out4.3% → —
- Dianthus Therapeutics−40%fewer sharesReduced6.5% → 4.2%
- Enliven Therapeutics+2.8 ppof portfolioNew— → 2.8%
- Sagimet Biosciences+2.5 ppof portfolioNew— → 2.5%
- Ascendis Pharma A/S+65%more sharesIncreased3.4% → 6.1%
- Monte Rosa Therapeutics−45%fewer sharesReduced3.9% → 3.0%
- Oruka Therapeutics+134%more sharesIncreased0.9% → 3.7%
- Definium Therapeutics+2.1 ppof portfolioNew— → 2.1%
- Abivax−44%fewer sharesReduced4.0% → 2.5%
- Kodiak Sciences−45%fewer sharesReduced4.5% → 2.4%
- Scholar Rock Holding−1.9 ppof portfolioSold out2.0% → —
- Alkermes plc.−75%fewer sharesReduced1.9% → 0.7%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Ascendis Pharma A/SASND6.1%
- CelcuityCELC5.8%
- Cogent BiosciencesCOGT5.5%
- UroGen PharmaURGN5.3%
- ImmunomeIMNM4.8%
- Dianthus TherapeuticsDNTH4.2%
- Rhythm PharmaceuticalsRYTM3.8%
- Oruka TherapeuticsORKA3.7%
- Monte Rosa TherapeuticsGLUE3.0%
- Syndax PharmaceuticalsSNDX3.0%
- Enliven TherapeuticsELVN2.8%
- ImmunovantIMVT2.7%
- ErascaERAS2.6%
- Sagimet BiosciencesSGMT2.5%
- AbivaxABVX2.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● SPAC / vehículos 1%
How its portfolio changed (8 quarters)
Q2 2026: 65
Q2 2026: 45%
Q2 2026: 29.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (8)
Besides stocks, Silverarc Capital Management declared 3 puts (they gain if the stock falls) and 5 calls (they gain if it rises) with a notional of $63.6M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTARK ETF Trnew this quarter$21.0M
- CALLSyndax PharmaceuticalsSNDX$15.2M
- CALLOric PharmaceuticalsORICnew this quarter$7.4M
- CALLMonte Rosa TherapeuticsGLUEnew this quarter$7.3M
- CALLAbivaxABVXnew this quarter$6.7M
- PUTKymera TherapeuticsKYMRnew this quarter$2.9M
- PUTAbsciABSInew this quarter$1.8M
- CALLFulcrum TherapeuticsFULC$1.4M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 30, 2026 (high confidence).
The data, as reported: SILVERARC CAPITAL MANAGEMENT, LLC (CRD 304220): 7.B private funds: 2 hedge, 1 vc (gross assets $935M); 5.D assets by client type: pooled vehicles 58%, corporations 42% (of $1.6 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Columbus Hill Capital ManagementInvestment firm · $899M
- TT International Asset ManagementInvestment firm · $898M
- North Peak Capital ManagementInvestment firm · $900M
- MayTech Global InvestmentsInvestment firm · $900M
- Nellore Capital ManagementInvestment firm · $901M
- Manchester Global Management (UK)Investment firm · $906M